There was one surprise, for me anyway, on page 50, regarding the $1 million worth of stock issuable to SMI in return for their initial $1 million up-front payment:
These shares have not been issued as of December 31, 2018.
Two other 10-K tidbits that I actually think might be mistakes -- sheesh, get your stories straight, Gene:
1. the 10-K says the CFDA still has not determined whether the device is Class II or Class III. (Gene said in his April 2 2019 PR "The Chinese FDA has determined that LuViva is a Class 2 medical device.")
2. The 10-K says that as of Dec 31 2018, SMI had paid only $750,000 of the initial $1 million payment. (Gene said in his Nov. 13 2018 PR "Shandong completed the last of its $1 million dollars in payments to Guided Therapeutics under the terms of the agreement between the two companies.")
News 
Market Data 
Discover 
